Allinaire Therapeutics has received $1.9 million in federal grants to support the development of treatments for lung diseases, including acute lung injury; Alpha-1 antitrypsin deficiency; and chronic obstructive pulmonary disease, or COPD.

The company received a $1.67 million Phase II SBIR grant from the National Heart, Lung and Blood Institute and a $213,000 Discovery Award from the U.S. Department of Defense.

Allinaire was formed by BioMotiv, a biotech accelerator associated with the Indiana University Research and Technology Corp., Innovate Indiana and BioCrossroads. The company’s lead project is based on technology exclusively licensed from IURTC, which is now known as the Indiana University Innovation and Commercialization Office.

More information about the grants is available online.